Sarcoma

Question 1

What are the components of MAID chemotherapy?

Answer 1

MESNA, adriamycin, ifosfamide, dacarbazine

Question 2

Pisters trial: P/D/R

Answer 2

P: 160 patients with extremity and superficial trunk sarcoma s/p WLE
D: adjuvant RT (brachy 45Gy) vs. observation
R: RT improved local control for high grade lesions (90% vs. 65%) but not for low grade lesions (70%)

Question 3

What were the local control rates for high grade sarcomas in the Pisters trial?

Answer 3

90% vs. 65%

Question 4

NCI (Yang) trial, low grade portion: P/D/R

Answer 4

P: extremity sarcoma s/p WLE
D: adjuvant RT (63Gy total) vs. observation
R: Local control improved with RT (95% vs. 60%)

Question 5

NCI (Yang) trial, high grade portion: P/D/R

Answer 5

P: extremity sarcoma s/p WLE
D: adjuvant chemo vs. adjuvant chemo-RT
R: Local control improved with RT (100% vs. 75%)

Question 6

What was the chemotherapy regimen used in the NCI (Yang) trial?

Answer 6

doxorubicine, cyclophosphamide

Question 7

NCI (Rosenberg) trial: P/D/R

Answer 7

P: 43 patients with high grade extremity sarcoma
D: amputation vs. WLE + adjuvant RT (60-70Gy total)
R: equivalent local control, DFS, and OS

Question 8

NCIC (O’Sullivan) trial: P/D/R

Answer 8

P: 190 patients with extremity sarcoma
D: neoadjuvant RT (50Gy) vs. adjuvant RT (66Gy)
R: equivalent local control, DFS, and OS; more wound healing issues with neoadjuvant (35% vs. 15%); more late fibrosis with adjuvant (48% vs. 31%)

Question 9

What were the rates of wound healing complications in the NCIC (O’Sullivan) trial?

Answer 9

35% vs. 15% (neoadjuvant vs. adjuvant)

Question 10

What were the rates of late fibrosis in the NCIC (O’Sullivan) trial?

Answer 10

31% vs. 48% (neoadjuvant vs. adjuvant)